[go: up one dir, main page]

MA63501A1 - Dérivés d'urée pouvant être utilisés pour traiter le cancer - Google Patents

Dérivés d'urée pouvant être utilisés pour traiter le cancer

Info

Publication number
MA63501A1
MA63501A1 MA63501A MA63501A MA63501A1 MA 63501 A1 MA63501 A1 MA 63501A1 MA 63501 A MA63501 A MA 63501A MA 63501 A MA63501 A MA 63501A MA 63501 A1 MA63501 A1 MA 63501A1
Authority
MA
Morocco
Prior art keywords
disease
treat cancer
urea derivatives
disorder
formula
Prior art date
Application number
MA63501A
Other languages
English (en)
Other versions
MA63501B1 (fr
Inventor
Maxwell David Cummings
Jean St Jr
Original Assignee
Scorpion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scorpion Therapeutics Inc filed Critical Scorpion Therapeutics Inc
Publication of MA63501A1 publication Critical patent/MA63501A1/fr
Publication of MA63501B1 publication Critical patent/MA63501B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente divulgation concerne des composés de formule (i), de formule (ii), et des sels pharmaceutiquement acceptables de ceux-ci, qui inhibent l'isoforme alpha de phosphatidylinositol 4,5-bisphosphate 3-kinase (pi3k). Ces entités chimiques sont utiles, par exemple, pour traiter une affection, une maladie ou un trouble dans lesquels une activation accrue (par exemple, excessive) de pi3ka contribue à la pathologie et/ou aux symptômes et/ou à la progression de l'affection, de la maladie ou du trouble (par exemple, un cancer) chez un sujet (par exemple, un être humain). Cette divulgation concerne également des compositions contenant lesdites entités, ainsi que des procédés d'utilisation et de fabrication de celles-ci.
MA63501A 2021-06-14 2022-06-13 Dérivés d'urée pouvant être utilisés pour traiter le cancer MA63501B1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163210370P 2021-06-14 2021-06-14
US202163228351P 2021-08-02 2021-08-02
US202163288909P 2021-12-13 2021-12-13
US202263316017P 2022-03-03 2022-03-03
US202263319236P 2022-03-11 2022-03-11
US202263348261P 2022-06-02 2022-06-02
PCT/US2022/033255 WO2022265993A1 (fr) 2021-06-14 2022-06-13 Dérivés d'urée pouvant être utilisés pour traiter le cancer

Publications (2)

Publication Number Publication Date
MA63501A1 true MA63501A1 (fr) 2024-03-29
MA63501B1 MA63501B1 (fr) 2024-07-31

Family

ID=82403494

Family Applications (1)

Application Number Title Priority Date Filing Date
MA63501A MA63501B1 (fr) 2021-06-14 2022-06-13 Dérivés d'urée pouvant être utilisés pour traiter le cancer

Country Status (19)

Country Link
US (5) US20240300939A1 (fr)
EP (1) EP4334298A1 (fr)
JP (2) JP7728367B2 (fr)
KR (1) KR20240035395A (fr)
AU (1) AU2022292554A1 (fr)
CA (1) CA3220039A1 (fr)
CL (1) CL2023003691A1 (fr)
CO (1) CO2023017150A2 (fr)
CR (1) CR20230576A (fr)
DO (1) DOP2023000271A (fr)
EC (1) ECSP23093675A (fr)
IL (1) IL309232A (fr)
MA (1) MA63501B1 (fr)
MX (1) MX2023014819A (fr)
PE (1) PE20250155A1 (fr)
TN (1) TN2023000286A1 (fr)
TW (1) TW202317526A (fr)
WO (1) WO2022265993A1 (fr)
ZA (1) ZA202311329B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20250155A1 (es) 2021-06-14 2025-01-22 Scorpion Therapeutics Inc Derivados de la urea que pueden ser utilizados para tratar el cancer
WO2024077036A1 (fr) * 2022-10-07 2024-04-11 Scorpion Therapeutics, Inc. Méthodes de traitement du cancer
WO2024097636A1 (fr) * 2022-10-31 2024-05-10 Scorpion Therapeutics, Inc. Polythérapie pour traitement du cancer
EP4611741A1 (fr) 2022-11-02 2025-09-10 Petra Pharma Corporation Ciblage de poches allostériques et orthostériques de phosphoinositide 3-kinase (pi3k) pour le traitement d'une maladie
TW202440124A (zh) * 2023-03-31 2024-10-16 大陸商長春金賽藥業有限責任公司 ＰＩ３Ｋα抑制劑化合物、藥物組合物及其用途
WO2024222894A1 (fr) * 2023-04-27 2024-10-31 Laekna Pharmaceutical Ningbo Co., Ltd. Composés de benzofurane et leur utilisation en tant qu'inhibiteurs de pi3k alpha
WO2024233256A1 (fr) 2023-05-05 2024-11-14 Eli Lilly And Company Imlunestrant ou sels de celui-ci destinés à être utilisés dans le traitement et la prévention de métastases du système nerveux central (snc) chez des sujets ayant un cancer du sein er+
WO2025002179A1 (fr) * 2023-06-27 2025-01-02 Laekna Pharmaceutical Ningbo Co., Ltd. Dérivés de n-[1-(2-benzofuranyl)-méthyl]-urée hétérotricycliques utilisés en tant qu'inhibiteurs de pi3k alpha pour le traitement du cancer
TW202509025A (zh) 2023-08-15 2025-03-01 美商史考皮恩治療有限公司 Ｐ１３ｋ抑制劑之結晶形式及其用途
WO2025038699A1 (fr) 2023-08-15 2025-02-20 Scorpion Therapeutics, Inc. Procédés de préparation d'inhibiteurs de pi3k
CN120623163A (zh) * 2024-03-11 2025-09-12 长春金赛药业有限责任公司 PI3Kα抑制剂化合物、药物组合物及其应用
WO2025231327A1 (fr) * 2024-05-03 2025-11-06 Scorpion Therapeutics, Inc. Agents de dégradation de pi3k et leurs procédés d'utilisation
WO2025247348A1 (fr) 2024-05-30 2025-12-04 Laekna Pharmaceutical Ningbo Co., Ltd. Composés hétéroaryles et leur utilisation en tant qu'inhibiteurs de pi3k alpha

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820834A (en) 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
US4735941A (en) 1986-12-23 1988-04-05 Merck & Co., Inc. 1,4-benzodiazepines with 5- and 6-membered heterocyclic rings, useful as gastrointestinal and CNS agents
EP0304223A3 (fr) 1987-08-17 1990-10-24 Merck & Co. Inc. Bêta-carbolines comme antagonists de la cholecy-stokinine et de la gastrine
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5032604A (en) 1989-12-08 1991-07-16 Merck & Co., Inc. Class III antiarrhythmic agents
US5324726A (en) 1989-12-18 1994-06-28 Merck & Co., Inc. Benzodiazepine analogs
CA2032427A1 (fr) 1989-12-18 1991-06-19 Mark G. Bock Analogues de benzodiazepines
CA2032226A1 (fr) 1989-12-18 1991-06-19 Mark G. Bock Analogues de la benzodiazepine
US5041453A (en) 1990-05-30 1991-08-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Quinolinyl-benzoheterobicyclic derivatives as antagonists of leukotriene D4
US5095031A (en) 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
CA2056809A1 (fr) 1990-12-07 1992-06-08 Mark G. Bock Analogues de la benzodiazepine
US5185331A (en) 1991-05-14 1993-02-09 Merck & Co., Inc. Triazolobenzodiazepines
US5206237A (en) 1991-05-14 1993-04-27 Merck & Co., Inc. Benzodiazepine analogs
CA2068500A1 (fr) 1991-05-14 1992-11-15 Roger M. Freidinger 1,4-benzodiazepines comportant des heterocycles a 5 et 6 chainons
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
EP0523846A3 (en) 1991-06-14 1993-03-17 Merck & Co. Inc. 1,4-benzodiazepines with 5-membered heterocyclic rings
CA2071181A1 (fr) 1991-06-14 1992-12-15 Roger M. Freidinger Analogues de la benzodiazepine
US5177071A (en) 1991-06-17 1993-01-05 Merck & Co., Inc. 1,4-benzodiazepines with 6-membered heterocyclic rings to treat panic and anxiety disorder
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
GB9117852D0 (en) 1991-08-19 1991-10-09 Merck Sharp & Dohme Therapeutic agents
EP0846694A1 (fr) 1992-01-23 1998-06-10 Toray Industries, Inc. Dérivés de morphinane et utilisation en médicine
EP0642498A1 (fr) 1992-05-28 1995-03-15 Pfizer Inc. NOUVEAU DERIVES $i(N)-ARYLE ET DE $i(N)-HETEROARYLUREE EN TANT QU'INHIBITEURS DE L'ACYLCOENZIME A: CHOLESTEROL ACYLTRANSFERASE (ACAT)
CA2144763A1 (fr) 1992-10-14 1994-04-28 George D. Hartman Antagonistes des recepteurs du fibrinogene
NZ268969A (en) 1993-07-23 1997-06-24 Toray Industries Morphinan derivatives and pharmaceutical compositions
CA2150345A1 (fr) 1993-09-28 1995-04-06 Makoto Komatsu Derives de quinoxaline utilises comme agents antidiabetiques
GB9408577D0 (en) 1994-04-29 1994-06-22 Fujisawa Pharmaceutical Co New compound
FR2725985B1 (fr) 1994-10-21 1996-11-15 Adir Nouveaux composes tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2734814B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes alkoxy-aryles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JPH11513684A (ja) 1995-10-19 1999-11-24 メルク エンド カンパニー インコーポレーテッド １６−置換−６−アザ−ステロイド５α−レダクターゼ阻害剤
US5821261A (en) 1995-12-08 1998-10-13 Merck & Co., Inc. Substituted saturated aza heterocycles as inhibitors of nitric oxide synthase
ES2215158T3 (es) 1996-11-25 2004-10-01 Toray Industries, Inc. Agente antipruritico.
WO1998049150A1 (fr) 1997-04-25 1998-11-05 Takeda Chemical Industries, Ltd. Derives de triazine, production de ces produits et composition agrochimique
KR100514963B1 (ko) 1997-07-11 2005-09-15 도레이 가부시끼가이샤 4,5-에폭시모르피난 유도체를 함유하는 안정한 의약품 조성물
AU6117298A (en) 1997-07-25 1999-02-16 Toray Industries, Inc. Hyponatremia remedies
CA2270955C (fr) 1997-09-02 2007-08-07 Toray Industries Inc. Composition pharmaceutique contenant un derive de morphinane pour le traitement de la dependance a une drogue
FR2778662B1 (fr) 1998-05-12 2000-06-16 Adir Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU4005299A (en) 1998-05-19 1999-12-06 Regents Of The University Of California, The Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
JP2000053572A (ja) 1998-08-11 2000-02-22 Toray Ind Inc ＯＲＬ１（ｏｐｉｏｉｄ ｏｒｐｈａｎ）受容体拮抗薬
JP2003524598A (ja) 1998-09-04 2003-08-19 アルタナ ファルマ アクチエンゲゼルシャフト 新規ピラノセン
AU761361B2 (en) 1998-09-25 2003-06-05 Astrazeneca Ab Benzamide derivatives and their use as cytokine inhibitors
US6444686B1 (en) 1998-12-18 2002-09-03 Brsitol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1058549A4 (fr) 1998-12-23 2003-11-12 Bristol Myers Squibb Pharma Co INHIBITEURS DU FACTEUR Xa OU DE LA THROMBINE
CN101070316A (zh) 1999-04-28 2007-11-14 萨诺费－阿文蒂斯德国有限公司 作为ppar受体配体的二芳基酸衍生物
EP1219624B1 (fr) 1999-08-24 2008-07-09 Toray Industries, Inc. Remedes contre les douleurs neuropathiques et modeles animaux de douleurs neuropathiques
JP2001163784A (ja) 1999-12-06 2001-06-19 Toray Ind Inc 角膜または結膜用止痒剤
AU2001239725A1 (en) 2000-01-13 2001-07-24 Tularik, Inc. Antibacterial agents
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
US6545152B1 (en) 2000-07-18 2003-04-08 Parker Hughes Institute R-isomers of nonnucleoside inhibitors
KR100893328B1 (ko) 2001-03-30 2009-04-14 도레이 카부시키가이샤 정신신경질환 약품
WO2002089845A1 (fr) 2001-05-08 2002-11-14 Toray Industries, Inc. Remedes contre la sepsie
SE0101978D0 (sv) 2001-06-01 2001-06-01 Astrazeneca Ab New compounds
MY130373A (en) 2001-10-29 2007-06-29 Malesci Sas Linear basic compounds having nk-2 antagonist activity and formulations thereof
KR20040106391A (ko) 2002-04-26 2004-12-17 니뽄 신야쿠 가부시키가이샤 퀴나졸린 유도체 및 의약
EP1578429A4 (fr) 2002-05-22 2006-12-06 Smithkline Beecham Corp Inhibiteurs de proteases
AU2003251828A1 (en) 2002-07-12 2004-02-02 Janssen Pharmaceutica N.V. Naphthol, quinoline and isoquinoline-derivatives as modulators of vanilloid vr1 receptor
JP2004083511A (ja) 2002-08-28 2004-03-18 Yamanouchi Pharmaceut Co Ltd アクリルアミド誘導体
WO2004022535A1 (fr) 2002-08-28 2004-03-18 Yamanouchi Pharmaceutical Co., Ltd. Derives d'acrylamide
BRPI0411098A (pt) 2003-06-05 2006-07-18 Warner Lambert Co benzofuranocarboxamidas, com atividade pi3k, como agentes terapêuticos
WO2005004810A2 (fr) 2003-07-02 2005-01-20 Merck & Co., Inc. Derives arylsulfonamide
GB0324498D0 (en) 2003-07-21 2003-11-26 Aventis Pharma Inc Heterocyclic compounds as P2X7 ion channel blockers
WO2005019190A2 (fr) 2003-08-20 2005-03-03 Vertex Pharmaceuticals Incorporated Composes d'aminofurazan utiles comme inhibiteurs de proteine-kinases
EP1723126A2 (fr) 2003-10-22 2006-11-22 Eli Lilly And Company Nouveaux antagonistes des recepteurs de l'hormone mch
NZ547109A (en) 2003-10-28 2010-03-26 Vertex Pharma Benzimidazoles useful as modulators of ion channels
EP1687289A1 (fr) 2003-11-20 2006-08-09 Eli Lilly And Company Modulateurs de recepteur de la vitamine d
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
TW200600494A (en) 2004-03-08 2006-01-01 Chugai Pharmaceutical Co Ltd Bisphenyl compounds useful as vitamin d3 receptor agonists
EP1751133B1 (fr) 2004-04-28 2010-04-14 Vertex Pharmaceuticals Incorporated Compositions utiles en tant qu'inhibiteurs de la rock et d'autres proteines kinases
US7893267B2 (en) 2005-03-14 2011-02-22 High Point Pharmaceuticals, Llc Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors
ES2351665T3 (es) 2005-03-24 2011-02-09 Rottapharm S.P.A. Derivados de benzamidina para el tratamiento y la prevención de mucositis.
ZA200800191B (en) 2005-06-09 2009-04-29 Vertex Pharmaceuicals Inc Indane derivatives as modulators of ion channels
WO2007026720A1 (fr) 2005-08-31 2007-03-08 Taisho Pharmaceutical Co., Ltd. Derive de pyrazole a noyau condense
US7897766B2 (en) 2005-09-23 2011-03-01 Abbott Laboratories Amino-aza-adamantane derivatives and methods of use
EP1934191B1 (fr) 2005-10-12 2012-03-28 Vertex Pharmaceuticals, Inc. Derives de biphenyle utilises comme modulateurs des canaux ioniques sensibles au voltage
WO2007075895A2 (fr) 2005-12-21 2007-07-05 Vertex Pharmaceuticals Incorporated Derives heterocycliques utilises comme modulateurs de canaux ioniques
CA2646469A1 (fr) 2006-03-21 2007-09-27 Epix Delaware, Inc. Composes modulant le recepteur de la sip
TW200815351A (en) 2006-05-02 2008-04-01 Astrazeneca Ab Novel compounds
WO2008013963A2 (fr) 2006-07-28 2008-01-31 University Of Connecticut Inhibiteurs d'hydrolase des amides d'acides gras
WO2008027483A1 (fr) 2006-08-31 2008-03-06 Arena Pharmaceuticals, Inc. Dérivés du benzofuranne utilisés comme modulateurs du récepteur 5-ht2a
PE20080888A1 (es) 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
US8796301B2 (en) 2007-04-24 2014-08-05 Toray Industries, Inc. Therapeutic or prophylactic agent for dyskinesia
CN101686976B (zh) 2007-04-26 2013-04-24 东丽株式会社 含有4,5-环氧基吗啡喃衍生物的稳定的固体制剂
WO2008154642A2 (fr) 2007-06-12 2008-12-18 Achaogen, Inc. Agents antibactériens
WO2008156573A1 (fr) 2007-06-12 2008-12-24 Provid Pharmaceuticals, Inc. Inhibiteurs de kinases, leurs compositions et procédés d'utilisation
BRPI0817804A8 (pt) 2007-10-05 2017-04-18 Toray Industries Agente terapêutico para melhorar as propriedades da pele compreendendo um derivado de morfinano ou qualquer um de seus sais de adição de ácido farmacologicamente permissíveis como um ingrediente ativo
CN101412692B (zh) 2007-10-18 2012-10-17 中国科学院上海药物研究所 1-(3-氨基丙基)哌啶-4-氨基酰胺类化合物、其药物组合物及其制备方法和用途
BRPI0907162A2 (pt) 2008-01-11 2015-07-07 Univ California Composto, composição farmacêutica e métodos para ativar procaspase executora 3, 6 e/ou 7 e para tratar um estado de doença em um mamífero
WO2009112445A1 (fr) 2008-03-10 2009-09-17 Novartis Ag Procédé d’accroissement de phosphatidyl-choline des cellules par l’inhibition de la dgat1
EP2282742A1 (fr) 2008-04-09 2011-02-16 Infinity Pharmaceuticals, Inc. Inhibiteurs d'hydrolase d'amide d'acide gras
US20110118234A1 (en) 2008-05-05 2011-05-19 Kaustav Biswas Urea Compounds as Gamma Secretase Modulators
KR101724161B1 (ko) 2008-08-27 2017-04-06 칼시메디카, 인크 세포내 칼슘을 조절하는 화합물
CN101712679B (zh) 2008-10-08 2013-04-10 中国科学院上海药物研究所 一种酰胺类化合物、其药物组合物及其制备方法和用途
DK2356989T3 (en) 2008-10-24 2018-05-07 Toray Industries Stable tablet containing 4,5-epoxymorphinane derivative
JP5535931B2 (ja) 2008-10-27 2014-07-02 武田薬品工業株式会社 二環性化合物
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
WO2010065681A1 (fr) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c de type ns5a
WO2010088574A1 (fr) 2009-01-30 2010-08-05 Sirtris Pharmaceuticals, Inc. Azabenzimidazoles et analogues apparentés en tant que modulateurs de la sirtuine
KR20110131312A (ko) 2009-03-27 2011-12-06 프레시디오 파마슈티칼스, 인코포레이티드 융합된 고리 ｃ형 간염 억제제
KR20120089459A (ko) 2009-08-24 2012-08-10 에즈셉피온 파마슈티컬즈, 인코포레이티드 키나제 저해제로서 5,6-바이사이클릭 헤테로아릴-함유 우레아 화합물
WO2011088181A1 (fr) 2010-01-13 2011-07-21 Tempero Pharmaceuticals, Inc. Composés et procédés
RU2554857C2 (ru) 2010-01-29 2015-06-27 Торэй Индастриз, Инк. Терапевтическое или профилактическое средство для заболеваний желчных путей
JP2013536806A (ja) 2010-09-01 2013-09-26 アスセピオン ファーマスーティカル、インコーポレイテッド キナーゼ阻害剤としての重水素化複素環式化合物
WO2012050918A2 (fr) 2010-09-29 2012-04-19 Presidio Pharmaceutical, Inc. Inhibiteurs de l'hépatite c tricyliques à cycles fusionnés
MX2013008749A (es) 2011-01-31 2013-10-17 Toray Industries Agente terapeutico o profilactico para caquexia.
EP2673264A1 (fr) 2011-02-10 2013-12-18 Syngenta Participations AG Dérivés de pyrazole microbiocides
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US9282738B2 (en) 2011-07-11 2016-03-15 Wisconsin Alumni Research Foundation Antimicrobial compositions and methods of use thereof
WO2013009810A1 (fr) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Méthodes de traitement
WO2013009830A1 (fr) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Méthodes de traitement
AU2012355619A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
PL2803662T3 (pl) 2012-01-13 2017-09-29 Nippon Chemiphar Co., Ltd. Antagonista receptora p2x4
DE102012103405A1 (de) 2012-04-18 2013-10-24 Heinrich-Pette-Institut Desoxyhypusin-Synthase-Inhibitoren
US20140200215A1 (en) 2013-01-15 2014-07-17 Intermune, Inc. Lysophosphatidic acid receptor antagonists
CN106659715A (zh) 2013-12-20 2017-05-10 药物发现研究所 取代的氨基三唑及其使用方法
KR20150136294A (ko) 2014-05-27 2015-12-07 주식회사 레고켐 바이오사이언스 인자 ＸＩａ 억제 활성을 가지는 신규한 화합물
EP2993174A1 (fr) 2014-09-08 2016-03-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Dérivés de pyrazolopyridine et leur utilisation en thérapie
JP6217866B2 (ja) 2014-10-24 2017-10-25 小野薬品工業株式会社 Ｋｃｎｑ２〜５チャネル活性化剤
KR20170139060A (ko) 2015-04-21 2017-12-18 올제네시스 바이오테라퓨틱스 아이엔씨. Bace1 억제제로서의 화합물 및 이의 용도
WO2017039318A1 (fr) 2015-09-01 2017-03-09 Kainos Medicine, Inc. Dérivés de benzimidazole pour des inhibiteurs de méthylation de l'adn
WO2017117447A1 (fr) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Composés multicycliques et leurs utilisations
ES2866324T3 (es) 2016-04-22 2021-10-19 Ono Pharmaceutical Co Derivados de 1-(1-hidroxi-2,3-dihidro-1H-inden5-il)-urea y compuestos similares como activadores del canal KCNQ2-5 para el tratamiento de la disuria
EP3452477B1 (fr) 2016-05-04 2023-09-13 B.C.I. Pharma Dérivés d'adénine en tant qu'inhibiteurs de protéines kinases
WO2018165501A1 (fr) 2017-03-10 2018-09-13 Lycera Corporation INDOLYLE SULFONAMIDE ET COMPOSÉS APPARENTÉS DESTINÉS À ÊTRE UTILISÉS EN TANT QU'AGONISTES DE RORγ ET POUR LE TRAITEMENT DE MALADIES
US11021471B2 (en) 2017-05-10 2021-06-01 Forge Therapeutics, Inc. Antibacterial compounds
WO2019111225A1 (fr) 2017-12-08 2019-06-13 Avaliv Therapeutics Composés et procédés destinés au traitement de la stéatohépatite non alcoolique
GB201809050D0 (en) 2018-06-01 2018-07-18 E Therapeutics Plc Modulators of tryptophan catabolism
WO2020028515A1 (fr) 2018-07-31 2020-02-06 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Interruption neuroprotectrice de l'interaction kv2.1/syntaxine par de petites molécules
CA3051422A1 (fr) 2018-08-09 2020-02-09 Kineta, Inc. Activateurs de la trajectoire du gene inductible par l`acide retinoique « rig-i » et procedes d`utilisation associes
EP3841221A4 (fr) 2018-08-23 2022-06-08 Memorial Sloan-Kettering Cancer Center Biomarqueurs pour déterminer la réactivité d'un cancer à des inhibiteurs de pi3k
CA3110619A1 (fr) 2018-09-03 2020-03-12 Nippon Chemiphar Co., Ltd. Medicament ciblant la neuropathie peripherique diabetique
CN111039942B (zh) 2018-10-12 2023-04-14 上海长森药业有限公司 含氮杂环类化合物，及其制备方法、药物组合物和应用
CA3136151A1 (fr) 2019-04-12 2020-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Composes agonistes du recepteur d3; procedes de preparation; intermediaires de ceux-ci; et leurs procedes d'utilisation
EP3967687A4 (fr) 2019-05-10 2023-01-18 Shanghai Haiyan Pharmaceutical Technology Co., Ltd Dérivé de phénylpropénylpyridine substitué, son procédé de préparation et son utilisation médicale
PE20250155A1 (es) 2021-06-14 2025-01-22 Scorpion Therapeutics Inc Derivados de la urea que pueden ser utilizados para tratar el cancer

Also Published As

Publication number Publication date
CO2023017150A2 (es) 2024-05-10
IL309232A (en) 2024-02-01
US11897871B1 (en) 2024-02-13
ZA202311329B (en) 2025-04-30
US20240300939A1 (en) 2024-09-12
EP4334298A1 (fr) 2024-03-13
US20240400543A1 (en) 2024-12-05
DOP2023000271A (es) 2024-03-28
CA3220039A1 (fr) 2022-12-22
CR20230576A (es) 2024-04-05
TN2023000286A1 (en) 2025-07-02
KR20240035395A (ko) 2024-03-15
MX2023014819A (es) 2024-03-21
JP2025134924A (ja) 2025-09-17
JP2024522192A (ja) 2024-06-11
WO2022265993A1 (fr) 2022-12-22
US12084434B2 (en) 2024-09-10
JP7728367B2 (ja) 2025-08-22
MA63501B1 (fr) 2024-07-31
ECSP23093675A (es) 2024-03-01
US20250250259A1 (en) 2025-08-07
AU2022292554A1 (en) 2024-01-04
TW202317526A (zh) 2023-05-01
US12312341B2 (en) 2025-05-27
US20240158376A1 (en) 2024-05-16
US20240076289A1 (en) 2024-03-07
CL2023003691A1 (es) 2024-06-07
PE20250155A1 (es) 2025-01-22

Similar Documents

Publication Publication Date Title
MA63501A1 (fr) Dérivés d'urée pouvant être utilisés pour traiter le cancer
MA63885A1 (fr) Composés inhibant l'isoforme alpha de pi3k et méthodes de traitement du cancer
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
MA30723B1 (fr) Benzoxazoles et oxazolopyridines utiles en tant qu'inhibiteurs des janus kinases.
MA30073B1 (fr) Derives de piperidine 3,5-substitues en tant qu'inhibiteurs de renine
TNSN08270A1 (fr) Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale
MA27647A1 (fr) Antagonistes de ccr5 utiles comme agents therapeutiques
MA31311B1 (fr) Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p)
MA29926B1 (fr) Derives de pyrazine
MA30351B1 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
MA30089B1 (fr) (arylsulfonyl)-pyrasolopiperidines
MA30916B1 (fr) Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
MA54386B1 (fr) Modulateurs de trex1
MA29543B1 (fr) Procedes pour traiter un cancer pharmacoresistant
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
MA30260B1 (fr) Acides 4-phenyl-thiazole-5-carboxyliques et amides d'acide 4-phenyl-thiazole-5-carboxylique en tant qu'inhibiteurs de plk 1
MA50013B1 (fr) Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton
MA60154A1 (fr) Inhibiteurs de line-1 pour traiter une maladie
TNSN06370A1 (fr) Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
MX2025004073A (es) Métodos para tratar el cáncer
MA54940B1 (fr) Dérivés d'acides aminés pour le traitement de maladies inflammatoires